A recent study suggests that patients who come off new slimming jabs like Mounjaro or Wegovy tend to recover reduced body mass much more quickly than those who stop traditional lifestyle programs.
Published data in a prominent medical journal demonstrates that while obese people often shed substantial amounts of their total mass while undergoing treatment, the mass returns at an estimated rate of 0.8 kg per month after stopping.
"People purchasing such medications need to be informed of the potential of fast rebound weight gain when the therapy is stopped," cautioned lead investigator Dr. Susan Jebb.
This pace of recovery implies a reversion to pre-treatment mass within about 18 months.
Comparing Therapies
The research, which looked at 37 of trials involving thousands of participants, compared the results of these new drugs with other pills.
The team note that individuals who shed pounds through dieting generally have a more gradual weight regain—perhaps 100 grams monthly—post-intervention.
Explaining the Fast Rebound
Doctors propose the mode of action of the drugs explains the heightened regain.
GLP-1 drugs copy a natural hormone called glucagon-like peptide-1, which helps regulate feelings of fullness.
"Artificially providing the hormone levels several times higher than normal may cause the system to generate a reduced amount of its endogenous GLP-1, and could reduce sensitivity to its effects," explained Dr. Adam Collins, a nutrition researcher.
"Withdrawal of this GLP-1 'fix' means appetite is uncontrolled, making excessive eating much more probable."
A Lifelong Disease?
The NHS recommend the jabs for individuals with obesity-related medical conditions, alongside prescribed lifestyle changes.
Professionals contend that, considering the significant potential of relapse, the therapy should be considered long-term.
This perspective is supported by pharmaceutical companies, who say that the findings "emphasize the long-term character of excess weight," comparing it to managing diseases like diabetes.
Patient Testimonies
People who have discontinued the medication describe a intense resurgence of hunger.
"It felt as if something flipping and I was suddenly extremely hungry," said one woman.
This challenge is compounded if patients have not adopted sustainable lifestyle or habit modifications during therapy.
Growing Use
Figures suggest that a significant number of people in the UK have tried these injections in the past year, with desire continuing to grow.
- Use is greater among females compared to men.
- The 40s and 50s age group shows the highest level of interest.
- A large proportion obtain the medications through private prescriptions rather than public health services.
Ultimately, experts caution that while these medications are powerful agents for shedding pounds, they are not a permanent cure and maintained weight loss likely depends on integrated behavioural changes.
